Bart N M Van Berckel

List of Publications by Year
in descending order

135 papers	7,031 citations	76326 40 h-index	66911 78 g-index
159 all docs	159 docs citations	159 times ranked	7873 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
2	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
3	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain, 2015, 138, 2732-2749.	7.6	397
4	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	2.6	307
5	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
6	Longitudinal Amyloid Imaging Using ^{11}C-PiB: Methodologic Considerations. Journal of Nuclear Medicine, 2013, 54, 1570-1576.	5.0	148
7	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	3.1	145
8	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
9	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
10	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimer's Research and Therapy, 2020, 12, 118.	6.2	129
11	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1–42 Analysis Results. Clinical Chemistry, 2018, 64, 576-585.	3.2	126
12	Detection of Alzheimer Pathology In Vivo Using Both ^{11}C-PIB and ^{18}F-FDDNP PET. Journal of Nuclear Medicine, 2009, 50, 191-197.	5.0	119
13	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	2.6	109
14	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping, 2014, 35, 2383-2393.	3.6	108
15	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. Neurology, 2018, 90, e149-e156.	1.1	103
16	Quantification of [^{18}F]DPA-714 Binding in the Human Brain: Initial Studies in Healthy Controls and Alzheimer'S Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 766-772.	4.3	99
17	Cerebral perfusion in the predementia stages of Alzheimer's disease. European Radiology, 2016, 26, 506-514.	4.5	99
18	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer's Research and Therapy, 2017, 9, 2.	6.2	98

#	Article	IF	Citations
19	ATN classification and clinical progression in subjective cognitive decline. Neurology, 2020, 95, e46-e58.	1.1	97
20	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
21	Optical coherence tomography angiography in preclinical Alzheimer's disease. British Journal of Ophthalmology, 2020, 104, 157-161.	3.9	95
22	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimer's Research and Therapy, 2018, 10, 76.	6.2	87
23	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
24	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 632-651.	6.4	82
25	Prediction of AD dementia by biomarkers following the NIA–AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
26	Visual Versus Semi-Quantitative Analysis of 18F-FDG-PET in Amnestic MCI: An European Alzheimer's Disease Consortium (EADC) Project. Journal of Alzheimer's Disease, 2015, 44, 815-826.	2.6	67
27	In vivo (R)-[11C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. NPJ Schizophrenia, 2016, 2, 16031.	3.6	63
28	Imaging of neuroinflammation in Alzheimer's disease, multiple sclerosis and stroke: Recent developments in positron emission tomography. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 425-441.	3.8	63
29	Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1629-1638.	6.4	62
30	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. Human Brain Mapping, 2017, 38, 4703-4715.	3.6	59
31	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
32	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 143-151.	2.4	57
33	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. PLoS ONE, 2014, 9, e102995.	2.5	56
34	Day-to-Day Test–Retest Variability of CBF, CMRO2, and OEF Measurements Using Dynamic 15O PET Studies. Molecular Imaging and Biology, 2011, 13, 759-768.	2.6	55
35	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
36	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54

#	Article	IF	Citations
37	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. Neurology, 2014, 82, 1768-1775.	1.1	51
38	The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimer's Research and Therapy, 2018, 10, 75.	6.2	48
39	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ^{18}F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. Journal of Nuclear Medicine, 2019, 60, 541-547.	5.0	47
40	In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy, 2021, 13, 35.	6.2	47
41	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
42	Clinical phenotype, atrophy, and small vessel disease in *APOE* Îµ2 carriers with Alzheimer disease. Neurology, 2018, 91, e1851-e1859.	1.1	46
43	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	6.4	44
44	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	2.6	42
45	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 563-584.	6.4	41
46	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. Neurology, 2022, 98, .	1.1	41
47	Discordant amyloid-Î² PET and CSF biomarkers and its clinical consequences. Alzheimer's Research and Therapy, 2019, 11, 78.	6.2	40
48	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. European Radiology, 2017, 27, 4237-4246.	4.5	37
49	Amyloid-Î² Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. Frontiers in Aging Neuroscience, 2019, 11, 7.	3.4	37
50	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
51	Is Verbal Episodic Memory in Elderly with Amyloid Deposits Preserved Through Altered Neuronal Function?. Cerebral Cortex, 2014, 24, 2210-2218.	2.9	36
52	Retinal layer thickness in preclinical Alzheimer's disease. Acta Ophthalmologica, 2019, 97, 798-804.	1.1	36
53	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 581-590.	2.6	35
54	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. Journal of the International Neuropsychological Society, 2021, 27, 426-438.	1.8	30

#	Article	IF	Citations
55	Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2866-2878.	6.4	29
56	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
57	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 3165-3175.	6.4	28
58	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
59	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatrics, 2018, 18, 289.	2.7	25
60	Comparison of Simplified Parametric Methods for Visual Interpretation of ^{11}C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	5.0	24
61	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2169-2182.	6.4	24
62	Parametric Binding Images of the TSPO Ligand ^{18}F-DPA-714. Journal of Nuclear Medicine, 2016, 57, 1543-1547.	5.0	23
63	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	2.7	23
64	The natural history of primary progressive aphasia: beyond aphasia. Journal of Neurology, 2022, 269, 1375-1385.	3.6	23
65	The Dopamine Stabilizer (−)-OSU6162 Occupies a Subpopulation of Striatal Dopamine D2/D3 Receptors: An [11C]Raclopride PET Study in Healthy Human Subjects. Neuropsychopharmacology, 2015, 40, 472-479.	5.4	22
66	Amyloid imaging of dutch‑type hereditary cerebral amyloid angiopathy carriers. Annals of Neurology, 2019, 86, 616-625.	5.3	22
67	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. Neuropsychologia, 2019, 131, 184-192.	1.6	22
68	Preclinical evaluation of [18F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors. Nuclear Medicine and Biology, 2015, 42, 205-212.	0.6	21
69	Partial volume correction of brain PET studies using iterative deconvolution in combination with HYPR denoising. EJNMMI Research, 2017, 7, 36.	2.5	21
70	PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. Alzheimer's Research and Therapy, 2019, 11, 100.	6.2	21
71	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. Annals of Neurology, 2021, 89, 987-1000.	5.3	20
72	Quantification of the novel N-methyl-D-aspartate receptor ligand [^{11}C]GMOM in man. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1111-1121.	4.3	19

#	Article	IF	Citations
73	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	2.5	19
74	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimer's Research and Therapy, 2021, 13, 133.	6.2	19
75	Model selection criteria for dynamic brain PET studies. EJNMMI Physics, 2017, 4, 30.	2.7	18
76	Amyloid-*β* PET and CSF in an autopsy-confirmed cohort. Annals of Clinical and Translational Neurology, 2020, 7, 2150-2160.	3.7	17
77	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	1.9	17
78	[11C]PIB amyloid quantification: effect of reference region selection. EJNMMI Research, 2020, 10, 123.	2.5	17
79	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 721-728.	6.4	16
80	White matter microstructure disruption in early stage amyloid pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12124.	2.4	16
81	[18 F]Flortaucipir PET Across Various *MAPT* Mutations in Presymptomatic and Symptomatic Carriers. Neurology, 2021, 97, e1017-e1030.	1.1	16
82	Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. Nuclear Medicine and Biology, 2014, 41, 670-680.	0.6	15
83	Synthesis, structure activity relationship, radiolabeling and preclinical evaluation of high affinity ligands for the ion channel of the N-methyl-d-aspartate receptor as potential imaging probes for positron emission tomography. Bioorganic and Medicinal Chemistry, 2015, 23, 1189-1206.	3.0	14
84	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. Neurobiology of Aging, 2019, 77, 58-65.	3.1	14
85	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
86	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2021, 76, 1499-1511.	3.9	14
87	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2020, 12, 138.	6.2	14
88	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. Alzheimer's Research and Therapy, 2021, 13, 82.	6.2	14
89	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. Brain Communications, 2021, 3, fcab201.	3.3	14
90	Performance of a modified supervised cluster algorithm for extracting reference region input functions from (R)-[<sup>11</sup>C]PK11195 brain PET studies. , 2008, , .		13

#	Article	IF	Citations
91	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 69-73.	2.4	13
92	Longitudinal retinal layer changes in preclinical Alzheimer's disease. Acta Ophthalmologica, 2021, 99, 538-544.	1.1	13
93	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. Neurocase, 2016, 22, 285-288.	0.6	12
94	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	7.6	12
95	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial. Alzheimer's and Dementia, 2023, 19, 285-295.	0.8	12
96	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. Journal of Neurology, 2019, 266, 2535-2545.	3.6	11
97	Contralateral improvement of cerebrovascular reactivity and TIA frequency after unilateral revascularization surgery in moyamoya vasculopathy. NeuroImage: Clinical, 2021, 30, 102684.	2.7	11
98	Synthesis, radiolabeling and evaluation of novel amine guanidine derivatives as potential positron emission tomography tracers for the ion channel of the N-methyl-d-aspartate receptor. European Journal of Medicinal Chemistry, 2016, 118, 143-160.	5.5	10
99	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. Molecular Imaging and Biology, 2021, 23, 604-613.	2.6	10
100	Synthesis, radiolabeling and preclinical evaluation of a [11 C]GMOM derivative as PET radiotracer for the ion channel of the N-methyl-D-aspartate receptor. Nuclear Medicine and Biology, 2017, 51, 25-32.	0.6	9
101	First in human evaluation of [18F]PK-209, a PET ligand for the ion channel binding site of NMDA receptors. EJNMMI Research, 2018, 8, 69.	2.5	9
102	Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. Annals of Clinical and Translational Neurology, 2021, 8, 348-358.	3.7	9
103	Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 529-537.	2.4	8
104	Evaluation of the Novel PET Tracer [11C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates. Molecular Imaging and Biology, 2019, 21, 676-685.	2.6	8
105	Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?. Journal of Alzheimer's Disease, 2020, 73, 559-569.	2.6	8
106	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1951-1963.	6.4	8
107	Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies. NeuroImage, 2021, 234, 117953.	4.2	7
108	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3033-3036.	6.4	6

#	Article	IF	Citations
109	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	2.5	6
110	Quantification of ^{11}C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5
111	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	3.7	5
112	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A Europeanâ€DLB consortium project. Alzheimer's and Dementia, 2021, 17, 1277-1286.	0.8	5
113	Design of the NLâ€ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 233-240.	3.7	4
114	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimerâ€™s Disease in Subjects with Mild Cognitive Impairment. Current Alzheimer Research, 2021, 17, 1186-1194.	1.4	4
115	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P14-P14.		3
116	Impact of New Scatter Correction Strategies on High-Resolution Research Tomograph Brain PET Studies. Molecular Imaging and Biology, 2016, 18, 627-635.	2.6	3
117	Binding characterization of N â€(2â€chloroâ€5â€thiomethylphenyl)â€N â€²â€(3â€[3 H] 3 methoxy phenyl)â€N â€²â€methylguanidine ([3 H] GMOM), a nonâ€competitive N â€methylâ€Dâ€aspartate (NMDA) receptor antagonist. Pharmacology Research and Perspectives, 2019, 7, e00458.	2.4	3
118	Human Dosimetry of the *N*-Methyl-d-Aspartate Receptor Ligand ^{11}C-GMOM. Journal of Nuclear Medicine, 2017, 58, 1330-1333.	5.0	2
119	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease, 2018, 65, 71-77.	2.6	2
120	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. Molecular Imaging and Biology, 2021, 23, 550-559.	2.6	2
121	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. Neurocase, 2021, 27, 181-189.	0.6	2
122	Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB. Molecular Imaging and Biology, 2021, 23, 335-339.	2.6	2
123	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P250-P250.		1
124	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, P248-P248.		1
125	IC-P-010: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, P12-P12.		1
126	Quantification of Tau Load in Alzheimerâ€™s Disease Clinical Trials Using Positron Emission Tomography. Methods in Molecular Biology, 2018, 1750, 221-229.	0.9	1

#	Article	IF	Citations
127	O4â€03â€01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.8	0
128	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
129	IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P11-P12.		0
130	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
131	IC-P-014: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P14-P14.		0
132	O2-05-03: USE OF CSF AMYLOID FOR DETECTING CORTICAL AMYLOID DEPOSITION: A MULTICENTER STUDY. , 2014, 10, P173-P173.		0
133	O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, P250-P251.		0
134	Increased 18 Fâ€flortaucipir load correlates with changes in MEG functional connectivity and network topology, as well as oscillatory slowing. Alzheimer's and Dementia, 2020, 16, e045911.	0.8	0
135	Generating parametric binding potential and volume of distribution images using a novel 2D basis function method and the two tissue compartment plasma input model. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S631-S631.	4.3	0